SCHEMBL3352213

SCHEMBL3352213

O=C1CSOc2ccccc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 7/20 0.42
ADORA3 P0DMS8 3/20 0.42
AR P10275 2/20 0.42
KDM4E B2RXH2 2/20 0.42
CYP19A1 P11511 1/20 0.42
HSD17B10 Q99714 1/20 0.42
PKM P14618 1/20 0.41
TSHR P16473 1/20 0.41
MAOA P21397 2/20 0.38
NPC1 O15118 2/20 0.37
MAPT P10636 2/20 0.37
RAB9A P51151 2/20 0.37
HSD11B1 P28845 1/20 0.37
AKR1C3 P42330 1/20 0.37
CYP3A4 P08684 1/20 0.37
MAPK1 P28482 1/20 0.37
ACHE P22303 1/20 0.36
TDP1 Q9NUW8 2/20 0.36
ALOX15 P16050 1/20 0.36
IDO1 P14902 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10504181 0.75 ACHE (0.41) MAOBKDM4EHSD17B10PKMTSHR
SCHEMBL1724509 0.69 MAOA (0.42) MAOBTSHRMAOAACHELMNA
SCHEMBL217973 0.69
SCHEMBL8814271 0.68 ACHE (0.52) MAOBKDM4ETSHRMAOAACHE
3-Coumaranone SCHEMBL69412 0.67 PKM (0.56) MAOBADORA3ARKDM4ECYP19A1
3-Coumaranone SCHEMBL29420742 0.67 PKM (0.56) MAOBADORA3ARKDM4ECYP19A1
SCHEMBL13104310 0.67 BRD4 (0.47) MAOBHSD17B10TSHRMAOANPC1
SCHEMBL9243850 0.67 KDM4E (0.43) KDM4EHSD17B10PKMTSHRMAPT
SCHEMBL224107 0.67 MAOB (0.42) MAOBADORA3ARKDM4ECYP19A1
SCHEMBL15789324 0.64 MAOA (0.42) MAOBKDM4EPKMTSHRMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7727997-B2 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARMACEUTICALS, INC. (US) 2010-06-01 US disclosed
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease ELAN PHARMACEUTICALS, INC. 2007-09-13 US disclosed
US-7176242-B2 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARMACEUTICALS, INC. (US) 2007-02-13 US disclosed
US-20040171881-A1 N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives PHARMACIA & UPJOHN COMPANY 2004-09-02 US disclosed
EP-0411751-A1 Renin inhibitory peptides Beecham Group p.l.c. (GB) 1991-02-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040171881-A1 N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives BACE1, BACE2, PSEN1 MAOB 442/4885ADORA3 921/4885AR 2694/4885
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease BACE1, BACE2, APP MAOB 803/4885ADORA3 1483/4885AR 3153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.